期刊文献+

乳腺癌的防治与临床治疗探讨 被引量:1

The discussion of breast cancer prevention and clinical diagnosis
下载PDF
导出
摘要 目的探讨乳腺癌临床诊治效果以及乳腺癌的防治。方法总结分析2006年5月~2008年10月来笔者所在医院就诊的60例乳腺癌患者的临床资料,在治疗的过程中根据患者的年龄、病理分期以及肿块的位置等选择手术方式。结果通过对本组60例乳腺癌患者临床实施手术后,全部病例均愈合出院,并且对本组全部患者3年以上随访可以得知,改良性根治手术3年生存率为94.12%,乳腺癌根治术3年患者生存率为84.62%。结论改良性根治手术是临床治疗乳腺癌的首先方法。并且加强对乳腺癌的防治,选择恰当的手术方法对提高乳腺癌患者的生存率具有重要的作用。 Objective To investigate the clinical diagnosis effect and prevention of breast cancer.Methods To analyze the clinical data of 60 cases of breast cancer patients who were treated in the author's hospital from May 2006 to October 2008,and then selected operation mode according to the patients' age,pathological stage and tumor location in the course of treatment.Results After clinical practice operation,the 60 cases of breast cancer patients in this group were all healed and discharged.After 3-year follow-up of all patients,we could informed that the survival rate of patients who had taken the modified radical operation was 94.12% for 3 years,and survival rate of patients who had taken the radical mastectomy operation was 84.62% for 3 years.Conclusion Modified radical operation is the first choice in clinical breast cancer treatment.And in order to improve the survival rate of breast cancer patients,it is very important to strengthen breast cancer prevention and choose appropriate operation method.
作者 闫永堂
出处 《中国医药科学》 2012年第23期177-177,179,共2页 China Medicine And Pharmacy
关键词 乳腺癌 临床治疗 防治措施 Breast cancer Clinical treatment Prevention
  • 相关文献

参考文献5

二级参考文献29

  • 1ALAOUI-JAMALI Moulay A..Review:Proteomic technology for biomarker profiling in cancer: an update[J].Journal of Zhejiang University-Science B(Biomedicine & Biotechnology),2006,7(6):411-420. 被引量:9
  • 2全国肿瘤防治研究办公室,卫生部信息统计中心.中国试点市、县恶性肿瘤的发病与死亡:1988-1997[M].北京:中国医药科技出版社,2002.23-25.
  • 3Wasinger VC, Cordwell SJ, Cerpa - Poljak A, et al. Progress with gene - product mapping of the Mollicutes : My coplasma genitalium [ J ]. Electrophoresis, 1995,16 (7) : 1090 - 1094.
  • 4O" Farrell PH. High resolution two - dimensional electrophoresis of proteins [ J], J Biol Chem, 1975,250:4007 - 4021.
  • 5Issaq H J, Veenstra TD, Conrads TP, et al. The SELDI - TOF - MS approach to proteomics : protein profiling and biomarker identification [ J ]. Biochem Biophys Res Commun, 2002, 292(3) :587 - 592.
  • 6Ransohoff DF. Bias as a threat to the validity of cancer molecular - marker research [ J ]. Nat Rev Cancer, 2005,5 (2) : 142 - 149.
  • 7Becker SM, Gregory B, Semmes OJ, et al. Discrimination of pre - and post - treatment breast cancer serum using SELDI - TOF MS ( surfaced - enhanced laser desorption/ionization -time of flight mass spectrometry) [ J ]. J Am Coil Surg, 2004,199 (3) :89 -92.
  • 8Li J, Zhang Z, Rosen Z, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer[ J ]. Clin Chem ,2002, 48 (8) : 1296 - 1304.
  • 9Zhang DH, Tai LK, Wang LL, et al. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors [ J ]. Proteomics ,2005,5 (7) : 1797 - 1805.
  • 10Ricolleau G, Charbonnel C, Lode L, et al. Surface -enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node - negative breast cancer tumors[ J]. Proteomics ,2006,6(6) : 1963 - 1975.

共引文献7

同被引文献19

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量:126
  • 2杨名添,戎铁华,黄植蕃,曾灿光,龙浩,傅剑华,林鹏,王欣,王思愚,王曦,唐军.可手术乳腺癌6263例临床分析[J].癌症,2005,24(3):327-331. 被引量:46
  • 3Goldhirsch A,Wood WC,Coates AS,et al. Strategies forsubtypes-dealing with the diversity of breast cancer : highlights ofthe St. Gallen International Expert Consensus on the PrimaryTherapy of Early Breast Cancer 2011 [ J]. Ann Oncol,2011 ,22(8):1736-1747. DOI: 10. 1093/annonc/mdr304.
  • 4Elston CW, Ellis 10. Pathological prognostic factors in breastcancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up [ J ],Histopathology, 1991,19 (5 ) :403410. DOI: 10. 1111/j. 1365-2559.1991. tb00229.x.
  • 5Goldhirsch A, Wood WC, Gelber RD, et al. Progress andpromise : highlights of the international expert consensus on theprimary therapy of early breast cancer 2007 [ J ]. Ann Oncol,2007,18(7) :1133-1144. D01:10. 1093/annonc/mdm271.
  • 6Seshie B, Adu-Aryee NA, Dedey F, et al. A retrospectiveanalysis of breast cancer subtype based on ER/PR and HER2status in Ghanaian patients at the Korle Bu Teaching Hospital,Ghana[ J]. BMC Clin Pathol, 2015, 15: 14. DOI: 10. 1186/sl2907-015-00144.
  • 7Zhu X, Ying J,Wang F, et al. Estrogen receptor, progesteronereceptor, and human epidermal growth factor receptor 2 status ininvasive breast cancer : a 3 ,198 cases study at National CancerCenter, China[ J] . Breast Cancer Res Treat,2014,147 (3 ) :551-555. DOI: 10.1007/sl0549-014-3136-y.
  • 8Kurian AW, Fish K, Shema SJ, et al. Lifetime risks of specificbreast cancer subtypes among women in four racial/ethnic groups[J]. Breast Cancer Res, 2010, 12 ( 6 ) : R99. DOI; 10. 1186/bcr2780.
  • 9Van Calster B, Vanden BI, Drijkoningen M, et al. Axillarylymph node status of operable breast cancers by combined steroidreceptor and HER-2 status : triple positive tumours are more likelylymph node positive[ J]. Breast Cancer Res Treat?2009 ,113( 1):181-187. DOI: 10.1007A10549-008-9914-7.
  • 10He Z Y, Wu S G, Yang Q, et al. Breast cancer subtype isassociated with axillary lymph node metastasis : A retrospectivecohort study [ J ]. Medicine ( Baltimore),2015 ,94 (48 ) ; e2213.DOI: 10. 1097/MD. 0000000000002213.

引证文献1

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部